Mayne Pharma Group Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Aaron Gray
- Full Time Employees
- 450
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1538 Main North Road Salisbury SA Australia 5106
- IPO Date
- Jun 29, 2007
- Website
- maynepharma.com
- Similar Companies
- Business
- Mayne Pharma Group Limited operates as a specialized pharmaceutical enterprise, involved in the development, manufacturing, and commercialization of both proprietary and unbranded medicinal products across Australia, New Zealand, the United States, Canada, Europe, and Asia. The company primarily focuses on women's health and dermatology, while also addressing therapeutic areas such as infectious diseases and pain management. Its operations are structured across segments including Women's Health, Dermatology, and International, which encompasses global manufacturing, sales of pharmaceutical goods, and contract development and manufacturing services for external clients. Mayne Pharma is recognized for its long-standing expertise in advanced oral drug delivery systems, a field in which it boasts a four-decade history of innovation. Notably, a recent proposal for the acquisition of Mayne Pharma by Cosette Pharmaceuticals, Inc. was formally rejected by the Australian Foreign Investment Review Board in November 2025, citing national interest concerns. The company traces its origins to its incorporation in 2005 and maintains its corporate headquarters in Salisbury South, Australia.
Company News
Mayne Pharma Group (OTCMKTS:MAYNF) Shares Down 8.8% – What’s Next?
Mayne Pharma Group Limited (MAYNF) Q4 2026 Earnings Call Transcript
Contrasting Otsuka (OTCMKTS:OTSKY) and Mayne Pharma Group (OTCMKTS:MAYNF)
Mayne Pharma Group Limited (MAYNF) Discusses U.S. Launch and Business Model of DistributeRx Transcript
Mayne Pharma Group Limited (MAYNF) Q2 2026 Earnings Call Transcript
Mayne Pharma Group (OTCMKTS:MAYNF) Stock Price Up 1.4% – Should You Buy?
Mayne Pharma Group Limited (MAYNF) Shareholder/Analyst Call Transcript
Mayne Pharma Group (OTCMKTS:MAYNF) Shares Down 9.7% – Here’s What Happened
Termination of Proposed Acquisition of Mayne Pharma
Australia Blocks U.S.-Based Cosette's $387.2 Million Takeover of Mayne Pharma
Australia blocks Cosette Pharmaceuticals bid to buy Mayne Pharma
Australia's Mayne Pharma falls as treasurer considers blocking Cosette's $437 million bid
Cosette's attempt to drop $438 million Mayne Pharma deal denied by court
Mayne Pharma slumps 30% as Cosette threatens to scrap $432 million deal
Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women's Health and Dermatology
FEDERAL CONTRACEPTION PROPOSAL TO EXPAND ACCESS AND AFFORDABLE COVERAGE PAVES A STRONGER PATH FOR MAYNE PHARMA'S GROWTH IN WOMEN'S HEALTH
Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringement
Mayne Pharma Group Limited (MAYNF) Q2 2024 Earnings Call Transcript